· Published by Health Canada · Official notice
This is duplicated text of a letter from GlaxoSmithKline Inc.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
October 26, 2010
Subject: Recall of Emo-Cort® (hydrocortisone) 2.5% Lotion, Lot 5R6, due to mould contamination
Dear Health Care Professional,
GlaxoSmithKline Inc. (GSK), in consultation with Health Canada, would like to inform health care professionals of a voluntary recall of one lot of the prescription medicine Emo-Cort® (hydrocortisone) 2.5% Lotion (DIN 00595802), 60mL bottle, Lot 5R6 (expiry date: May 2012). The bottle is branded as a Stiefel product. Two bottles from this lot were found to contain the mould Paecilomyces variotii.
Although Paecilomyces variotii is a commonly occurring mould species, it is associated with many types of human infections and is listed among the emerging causative agents of opportunistic mycoses in immunocompromised hosts. Overall, topical exposure to Paecilomyces variotii is unlikely to pose significant risk to consumer safety in non-immunocompromised individuals; however, in immunocompromised patients, there is a potential risk of localized and systemic infections, which can be severe.
For these reasons, GSK has decided to recall Lot 5R6 of Emo-Cort® 2.5% Lotion at the wholesaler, distributor and pharmacist levels as of October 15, 2010 and has voluntarily stopped the manufacture and distribution of all Emo-Cort® products as a precautionary measure.
To date GSK has not received any reports of adverse events associated with Lot 5R6 of Emo-Cort® 2.5% Lotion.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious or unexpected adverse reactions in patients receiving Emo-Cort® 2.5% Lotion should be reported to GlaxoSmithKline Inc. or Health Canada at the following addresses:
GlaxoSmithKline Inc.
7333 Mississauga Road North
Mississauga, Ontario
L5N 6L4
Telephone: 1-800-387-7374
You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following three ways:
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.
For other health product inquiries related to this communication, please contact Health Canada at:
Health Product and Food Branch Inspectorate (HPFBI)
E-mail: DCVIU_UVCEM@hc-sc.gc.ca
Telephone: 1-800-267-9675
Fax: 1-613-946-5636
To change your mailing address or fax number, contact the Market Authorization Holder (Industry).
Sincerely,
original signed by
Dr. Tjark Reblin, MD, MBA
Vice President, Medical Division and Chief Medical Officer
GlaxoSmithKline Inc.
® Emo-Cort is a registered trade-mark, used under license by GlaxoSmithKline Inc.